Celltrion May Apply for FDA Approval for Rituximab and Trastuzumab by June

Biosimilar News

The Korea Herald reports that Celltrion is on track to file applications for U.S. FDA approval for its rituximab and trastuzumab biosimilars by June.  According to the article (and as previously reported), once approved, the drugs will be sold through Celltrion’s U.S. commercial partner, Teva Pharmaceutical Industries Ltd.

Download PDF

Comments are closed.